Should I buy or sell Hikma Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HKMPF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HKMPF, but not buy additional shares or sell existing shares. View HKMPF analyst ratings or view top-rated stocks .

How have HKMPF shares performed in 2024?

Hikma Pharmaceuticals' stock was trading at $22.7850 at the beginning of 2024. Since then, HKMPF stock has decreased by 2.0% and is now trading at $22.33. View the best growth stocks for 2024 here .

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals declared a dividend on Wednesday, March 6th. Stockholders of record on Friday, March 22nd will be given a dividend of $0.47 per share on Friday, May 3rd. The ex-dividend date is Wednesday, March 20th. This is a positive change from the stock's previous dividend of $0.25. Read our dividend analysis for HKMPF .

Is Hikma Pharmaceuticals a good dividend stock?

Hikma Pharmaceuticals (OTCMKTS:HKMPF) pays an annual dividend of $0.94 per share and currently has a dividend yield of 3.88%. Read our dividend analysis for HKMPF .

How do I buy shares of Hikma Pharmaceuticals?

Shares of HKMPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:HKMPF

Hikma Pharmaceuticals (HKMPF) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free HKMPF Stock Alerts

$22.33

-1.92 (-7.92%)

(As of 04/17/2024 ET)

Compare

Today's Range: $22.33
▼
$22.33
50-Day Range: $22.33
▼
$26.50
52-Week Range: $21.28
▼
$27.15

Volume: 204 shs
Average Volume: 186 shs
Market Capitalization: $4.92 billion

P/E Ratio: N/A
Dividend Yield: 4.21%
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Dividend Headlines Short Interest

Get Hikma Pharmaceuticals alerts:

Ad InvestorPlace

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Hikma Pharmaceuticals Stock (OTCMKTS:HKMPF)

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

HKMPF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HKMPF Stock News Headlines

March 20, 2024 | msn.com

Hikma Pharmaceuticals PLC goes ex dividend tomorrow

March 18, 2024 | finance.yahoo.com

Optimism around Hikma Pharmaceuticals (LON:HIK) delivering new earnings growth may be shrinking as stock declines 3.3% this past week

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

February 27, 2024 | finance.yahoo.com

Hikma Pharmaceuticals PLC (HKMPF)

February 22, 2024 | msn.com

Drugmaker Hikma expects profit to be slightly lower in 2024

February 22, 2024 | markets.businessinsider.com

Hikma Pharma FY Profit Increases

February 1, 2024 | msn.com

Hikma Pharmaceuticals did not report suspicious opioid orders for 15 years, NC Attorney General Josh Stein says

February 1, 2024 | marketwatch.com

Hikma Pharmaceuticals Agrees in Principle to Pay up to $115M in US Opioid Settlement

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

February 1, 2024 | finance.yahoo.com

Ad firm Publicis, drugmaker Hikma settle US opioid cases for $500 million

February 1, 2024 | finance.yahoo.com

UPDATE 1-Ad firm Publicis, drugmaker Hikma settle US opioid cases for $500 million

January 29, 2024 | finance.yahoo.com

Hikma Pharmaceuticals PLC's (LON:HIK) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

October 5, 2023 | finance.yahoo.com

The one-year decline in earnings might be taking its toll on Hikma Pharmaceuticals (LON:HIK) shareholders as stock falls 3.3% over the past week

October 3, 2023 | finance.yahoo.com

Stocks Open Lower, Weighed Down by Rising Bond Yields

August 10, 2023 | finance.yahoo.com

Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox™ Platform Cancer Treatment in the Middle East and North Africa

August 9, 2023 | marketwatch.com

Hikma Appoints Bill Larkins as President of Injectables Business

July 26, 2023 | finance.yahoo.com

Hikma Ventures invests in Octave Bioscience, a precision care platform for Multiple Sclerosis and other neurodegenerative diseases

May 6, 2023 | msn.com

Selling Hikma Pharmaceuticals After A 40% Share Price Gain In 7 Months

April 12, 2023 | lse.co.uk

Hikma Pharmaceutical appoints Injectables lead Mishlawi as new CEO

April 12, 2023 | nasdaq.com

Hikma Pharma Appoints Riad Mishlawi As CEO, Effective Sept. 1

April 12, 2023 | marketwatch.com

Hikma Pharmaceuticals Appoints Riad Mishlawi CEO

April 12, 2023 | msn.com

Hikma Pharma names Mishlawi as next CEO

April 4, 2023 | finance.yahoo.com

Those who invested in Hikma Pharmaceuticals (LON:HIK) five years ago are up 57%

March 18, 2023 | marketwatch.com

Hikma Pharmaceuticals rises Thursday, still underperforms market

March 15, 2023 | marketwatch.com

Hikma Pharmaceuticals falls Monday, still outperforms market

March 9, 2023 | finance.yahoo.com

Hikma expands impact in Canada with launches of new sterile injectable medicines

February 27, 2023 | finance.yahoo.com

Is Hikma Pharmaceuticals PLC's (LON:HIK) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

See More Headlines

Receive HKMPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 5/3 Dividend: 3/20/2024
Today: 4/19/2024
Dividend Payable: 5/03/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Private households
Sub-Industry: N/A
Current Symbol: OTCMKTS:HKMPF
Previous Symbol: OTC:HKMPF
CUSIP: N/A
CIK: N/A
Web: www.hikma.com
Phone: 442073992760
Fax: 44-20-7399-2761
Employees: 8,800
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.47
Current Ratio: 1.57
Quick Ratio: 0.90

Sales & Book Value

Annual Sales: $2.88 billion
Price / Sales: 1.71
Cash Flow: $3.06 per share
Price / Cash Flow: 7.29
Book Value: $10.03 per share
Price / Book: 2.23

Miscellaneous

Outstanding Shares: 220,230,000
Free Float: N/A
Market Cap: $4.92 billion
Optionable: Not Optionable
Beta: 0.50

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Engineer Said Samih Taleb Darwazah (Age 67)
Executive Chairman
Comp: $2.8M
Mr. Riad Ali Mishlawi (Age 60)
CEO & Director
Comp: $1.1M
Mr. Mazen Samih Taleb Darwazah (Age 66)
Executive Vice Chairman & President of MENA
Comp: $2.3M
Mr. Khalid Waleed Hosny Al Nabilsi (Age 52)
Chief Financial Officer
Patricia Bousfield
Chief Information Officer
Mr. Guy Featherstone
Associate Director of Investor Relations
Mr. Samuel Park
General Counsel
Mr. Bassam Wael Rushdi Kanaan CFA (Age 59)
CPA, Executive Vice President of Corporate Development and M&A
Mr. Hussein Omar Arkhagha
Chief People Officer
Ms. Susan Ringdal
Executive Vice President of Strategic Planning & Global Affairs

Key Competitors

View All Competitors

HKMPF Stock Analysis - Frequently Asked Questions

Should I buy or sell Hikma Pharmaceuticals stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HKMPF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HKMPF, but not buy additional shares or sell existing shares.
View HKMPF analyst ratings or view top-rated stocks.
How have HKMPF shares performed in 2024?: Hikma Pharmaceuticals' stock was trading at $22.7850 at the beginning of 2024. Since then, HKMPF stock has decreased by 2.0% and is now trading at $22.33.
View the best growth stocks for 2024 here.
How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?: Hikma Pharmaceuticals declared a dividend on Wednesday, March 6th. Stockholders of record on Friday, March 22nd will be given a dividend of $0.47 per share on Friday, May 3rd. The ex-dividend date is Wednesday, March 20th. This is a positive change from the stock's previous dividend of $0.25.
Read our dividend analysis for HKMPF.

Is Hikma Pharmaceuticals a good dividend stock?: Hikma Pharmaceuticals (OTCMKTS:HKMPF) pays an annual dividend of $0.94 per share and currently has a dividend yield of 3.88%.
Read our dividend analysis for HKMPF.
How do I buy shares of Hikma Pharmaceuticals?: Shares of HKMPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:HKMPF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Hikma Pharmaceuticals (HKMPF) Stock Price, News & Analysis

About Hikma Pharmaceuticals Stock (OTCMKTS:HKMPF)

HKMPF Stock Price History

HKMPF Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

HKMPF Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info